Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We report the synthesis and biological evaluation of a small library of 15 functionalized 3-styryl-2-pyrazolines and pyrazoles, derived from curcuminoids, as trypanosomicidal agents. The compounds were prepared via a cyclization reaction between the corresponding curcuminoids and the appropriate hydrazines. All of the derivatives synthesized were investigated for their trypanosomicidal activities. Compounds and showed significant activity against epimastigotes of , with IC values of 5.0 and 4.2 μM, respectively, accompanied by no toxicity to noncancerous mammalian cells. Compound was found to effectively inhibit triosephosphate isomerase. The up to 16-fold higher potency of these derivatives compared with their curcuminoid precursors makes them a promising new family of inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/fmc-2020-0349 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, Synthesis, and Molecular Docking Studies of Novel Pyrazoline-Thiazoles as Cholinesterase Dual-Target Inhibitors for the Treatment of Alzheimer's Disease.
ACS Omega
September 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
Ten novel pyrazoline-thiazole derivatives were synthesized and assessed for their potential as acetylcholinesterase and butyrylcholinesterase inhibitors. The structure of the target compounds was characterized by H NMR and C NMR, and purity was determined using HPLC. The in vitro enzyme inhibitory activity assays determined that compounds (IC = 0.
View Article and Find Full Text PDFDiscovery of Furopyrimidine-Pyrazole Hybrid Compounds Targeting p53-MDM2 Interaction as Anticancer Agents.
Arch Pharm (Weinheim)
September 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt.
Inhibiting the p53-MDM2 interaction restores the function of the tumour suppressor protein, p53, and offers a promising avenue for anticancer therapies. Herein, a novel series of pyrazoline-derived compounds was developed and synthesised to serve as potential inhibitors of the p53-MDM2 interaction. Scaffold hopping was adopted via replacing the cis-imidazoline core of Nutlin-2 with a pyrazoline core, and molecular docking confirmed the binding orientation of the designed compounds at the p53-MDM2 interaction site.
View Article and Find Full Text PDFIntegrated computational and preclinical evaluation of novel synthetic pyrazole pyrazoline thiazole derivative for breast cancer therapeutics.
Sci Rep
August 2025
Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Gujarat, India.
Breast cancer is the uncontrolled growth of breast cells in the lobules or the inner lining of milk ducts due to dysfunction of regulatory genes. The drugs currently used in breast cancer treatment have severe limitations. The study aimed to test 10 new synthetic forms of pyrazole clubbed pyrazoline thiazole derivatives for their ability to kill tumor cells, reduce inflammation, fight free radicals, and other important factors linked to breast cancer.
View Article and Find Full Text PDFFrom Lab to Target: Pyrazole, Pyrazoline and Fused Pyrazole Derivatives as Receptor Tyrosine Kinase Inhibitors in Cancer Therapy.
Arch Pharm (Weinheim)
August 2025
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Pyrazole derivatives have emerged as versatile scaffolds in the development of receptor tyrosine kinase inhibitors, offering promising avenues for targeted cancer therapy. Their therapeutic potential in cancer therapy is notable in many FDA-approved anticancer drugs. This review provides a comprehensive overview of the latest research from 2021 regarding novel pyrazole, pyrazoline, and fused pyrazole derivatives targeting receptor tyrosine kinases, namely: AXL, DDR, EGFR, FGFR, MET, CSF1R, RET, and VEGFR-2.
View Article and Find Full Text PDFHerein, we report an interesting [3 + 2] annulation/ring-opening cascade reaction between hydrazones and exocyclic dienones an aerobic, copper(ii) catalysis to synthesize 5-(pyrazol-4-yl) pentanoic acid and 4-(pyrazol-4-yl) butanoic acid derivatives. The annulation first affords a spiro pyrazoline with unprecedented regiochemistry, followed by a cascade nucleophilic ring opening by water to yield pyrazolyl pentanoic and butanoic acid derivatives in good yield. Broad substrate scope, inexpensive and green catalyst and oxidant, and relatively mild reaction conditions enhance the versatility of this protocol.
View Article and Find Full Text PDF